-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s V-116
Empower your strategies with our Net Present Value Model: Merck & Co Inc's V-116 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s V-184
Empower your strategies with our Net Present Value Model: Merck & Co Inc's V-184 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – StemVacs-V in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - StemVacs-V in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. StemVacs-V in Metastatic Breast Cancer Drug Details: StemVacs-V is under development...
-
Product Insights
V-Mars San Jose Solar Power Project 1, Philippines
V-Mars San Jose Solar Power Project 1 is proposed to be built in Central Luzon, Philippines. The project is at the permitting stage. Empower your strategies with our V-Mars San Jose Solar Power Project 1 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed...
-
Product Insights
Integrin Alpha V – Drugs In Development, 2023
Global Markets Direct’s Integrin Alpha V provides in depth analysis on Integrin Alpha V targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha V targeted therapeutics...
-
Product Insights
Real Mgmt – Good Point V logistics complex – Masovian Voivodeship
The Real Mgmt – Good Point V logistics complex – Masovian Voivodeship project involves the construction of a 30,000m2 logistics complex on 13.3ha of land in Masovian Voivodeship, Poland. Equip yourself with the essential tools needed to make informed and profitable decisions with our Real Mgmt – Good Point V logistics complex – Masovian Voivodeship report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGS-v PLUS in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGS-v PLUS in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGS-v PLUS in Malaria Drug Details: AGS-v PLUS is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGS-v PLUS in Dengue Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGS-v PLUS in Dengue Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGS-v PLUS in Dengue Fever Drug Details: AGS-v PLUS is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGS-v PLUS in Yellow Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGS-v PLUS in Yellow Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGS-v PLUS in Yellow Fever Drug Details: AGS-v PLUS is under...
-
Product Insights
Transient Receptor Potential Cation Channel Subfamily V Member 1 – Drugs In Development, 2023
Global Markets Direct’s Transient Receptor Potential Cation Channel Subfamily V Member 1 provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily V Member 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides...